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ABSTRACT 
The COVID-19 pandemic is yet to be over. Although the number of pediatric patients is 
relatively small, their clinical manifestations differ from the adult group. Multisystem 
Inflammatory Syndrome in Children (MIS-C) is one of the most recently discussed clinical 
manifestations. The clinical features of this case resemble those of Kawasaki disease or toxic 
shock syndrome with limited diagnostic methods. Patients experience gastrointestinal, 
mucocutaneous, cardiovascular, hematological, and neurological symptoms. There was also an 
increase in inflammatory parameters and cardiac disorders, which will also be confirmed by 
electrophysiological and radiological examinations. Management consists of the administration 
of immunoglobulins, steroids, and some anti-cytokines. When the patient goes into shock, fluid 
resuscitation is the mainstay of therapy. Until now, the number of MIS-C patients is relatively 
small compared to the number of COVID-19 cases, and the number of deaths is very minimal as 
well. 
Keywords: Multisystem Inflammatory Syndrome, Children, COVID-19, SARS-Cov-2, Kawasaki 
Disease  
ABSTRAK 
Pandemi COVID-19 belum berlalu. Sekalipun jumlah pasien anak relatif sedikit, manifestasi 
klinik banyak berbeda dengan kelompok dewasa. Salah satu bentuk yang menyerang anak adalah 
Multisystem inflammatory syndrome yang menyerupai penyakit Kawasaki maupun Sindroma 
Syok Toksik. Anak yang terkena akan menunjukkan gejala dan tanda gastrointestinal, 
mukokutaneus, kardiovaskular, hematologi, dan neurologi. Pada anak akan dijumpai peningkatan 
parameter inflamasi serta kelainan jantung yang akan terkonfirmasi dengan pemeriksaan 
elektrofisiologi dan radiologi. Tatalaksana mencakup imunoglobulin, steroid, dan beberapa 
antisitokin. Bila pasien dalam keadaan syok, resusitasi cairan adalah tindakan utama. Hingga saat 
ini jumlah penderita MIS-C relatif kecil dengan angka kematian yang juga kecil. 
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 The COVID-19 outbreak was first 
reported towards the end of 2019 in Wuhan, 
China.1,2 As of August 2020, no effective 
medicines and vaccines have been 
discovered, and the pandemic is yet to be 
under control.3,4 While there are relatively 
few pediatric patients worldwide compared 
to the number of adult patients, the two age 
groups have some significant 
differences.1,2,5,6  One of the differences 
concerns clinical manifestations. In children, 
the manifestations of the disease are more 
diverse than in adults.2,5-7 The dominance of 
respiratory symptoms and signs, for 
example, is not as dominant in the adult 
group.2,6,7 Children also obtained a specific 
clinical spectrum that resembles Kawasaki 
disease (KD) and Toxic Shock Syndrome 
(TSS).8-10 This unique spectrum is reported 
from many publications.11 
 The disease that occurs after SARS-
CoV-2 infection can be of several types, all 
of which are immunological and 
inflammatory manifestations. These 
conditions include Kawasaki-like disease, 
Kawasaki disease shock syndrome (KDSS), 
TSS, myocarditis, and macrophage 
activation syndrome (MAS). The entire 
spectrum is then grouped and is called the 
Multisystem Inflammatory Syndrome in 
Children (MIS-C) or Pediatric Inflammatory 
Multisystem Syndrome (PIMS).9,12-16 Some 
clinicians also consider MIS-C as consisting 
of 3 major groups, namely the group 
characterized by shock, the Kawasaki 
disease group, and the fever group with 
inflammation.8,17 KD itself has been known 
since 1960s. Dr. Tomisaku Kawasaki carried 
out the first publication based on 
observations of 50 children in Japan. He 
mentioned “acute febrile mucocutaneous 
lymph node syndrome”.18 This disease is 
common in East Asia. Until now, the cause 
of the disease is not clear, and none of the 
suspected causal microorganisms have yet 
been found.11,19-21 
 By the end of June 2020, there were 
more than 1400 publications regarding MIS-
C in several world data sources, including 
preprints.20 This large number shows cases 
of MIS-C were observed in several places in 
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THE NAME OF DISEASE 
 There are several names used to 
describe the diagnosis of this disease. The 
Royal College of Paediatrics and Child 
Health (RCPCH) in the UK named it the 
Pediatric Multisystem Inflammatory 
Syndrome temporarily associated with 
COVID-19.22 The Center for Disease 
Control and Prevention (CDC) and the 
American College of Rheumatology (ACR) 
in the US call it the Multisystem 
Inflammatory Syndrome in Children 
Associated with COVID-19 (MIS-C),23,24 
while the European CDC (ECDC) referred 
to it as Pediatric Inflammatory Multisystem 
Syndrome temporally associated with 
SARS-CoV-2 (PIMS-TS).16 Those names 
are intended for the same clinical spectrum. 
The WHO published the name Multisystem 
Inflammatory Disorder in Children and 
Adolescents on May 15, 2020.25 
 Given that the spectrum of disease is 
not uniform and is relatively complex, the 
correct name is very important so that its 
interpretation is the same by everyone.26 In 
this paper, for uniformity, the name used is 
MIS-C. 
FIRST REPORTS 
The first report of MIS-C was 
published in the UK on 25 April 2020 when 
the National Health Service (NHS) alerted 
its staff to critical cases with depictions of 
TSS, atypical Kawasaki, and severe 
COVID-19 infection.20,21,27 The RCPCH 
officially issued guidelines on May 1, 2020, 
specifically addressing this disease. A report 
followed the UK publication in the journal 
named Lancet on May 6, 2020, which 
discussed 8 cases of MIS-C. 13 A report was 
published in Bergamo, one of the epicenters 
of COVID-19 in northern Italy, at the same 
time as when about 10 cases arose that 
showed symptoms similar to KD and/or 
TSS.9 Eight of the children had tested 
positive for the SARS-CoV-2 
immunoglobulin. In the two months of 
observation since February 2020, the 
number of KD-like diseases in that area was 
30 times higher than the same period in 
previous years. Patients in 2020 are also 
relatively older and more likely to 
experience shock.9 The ECDC report on the 
same was published on 12 May 2020, in 
France.16 This report mentions 125 cases in 
children. A publication from Paris listed 17 
cases in the initial report.14 The CDC report 
in the United States on May 14, 2020, stated 
that the first detection occurred on April 7, 
2020, in a 6-month-old baby. There were 
three deaths in one month of monitoring. 
From 17 April to 4 May of 2020, 15 cases 
were detected, with 4 cases still showing 
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positive PCR results. Six out of 10 cases 
with negative PCR results had SARS-CoV-2 
antibodies. On 10 May 2020, the number of 
cases had reached 85 with three deaths. On 
12 May 2020, a total of 102 cases were 
reported, with 29% being in the age group of 
5–9 years and 28% in the age group of 10–
14 years.23 The ECDC report dated 15 May 
2020, mentioned 224 cases throughout 
Europe and Great Britain with two deaths (1 
in England and 1 in France).16 Until that 
date, there were no cases in other countries 
such as Japan, Greece, and Sweden. By the 
end of June, it was estimated that 1000 cases 
of MIS-C had been reported in various 
countries. These reports use a variety of case 
definitions.28 
EPIDEMIOLOGY UP TO MID-
AUGUST, 2020 
 There have been various case reports 
from many countries.11 All of Western 
Europe arguably identified this case. In the 
US, reports came from various states across 
the country, with New York as the main 
epicenter. Many publications have also 
emerged from the Middle East. 
Interestingly, there have been no reports 
from Australia, New Zealand, or East 
Asia.11 The majority of cases of MIS-C, in 
contrast to cases of KD, were mostly in 
those with African, African-American, and 
Afro-Caribbean backgrounds.8,10,20,29-32 In 
the US, the Hispanic group is the most 
affected.10,30,33 These racial differences can 
be caused by genetic or social factors such 
as economic conditions and degree of 
exposure.24,31 
 In the systematic review written by 
Abrams et al., from the end of April to the 
end of June 2020, there were at least 440 
cases reported in 8 publications. Two 
publications came from the US while the 
remaining six were from Europe.8-10,13-
15,20,30,31 Only reports of more than 5 cases 
were included in this study.20 Patients with 
KD are relatively younger than those with 
MIS-C. If KD attacks children less than 2 
two years old, MIS-C patients' average age 
is ten years.8,9,15,20,31,32,34-37 Being five years 
of age or older is a risk factor for a severe 
condition, as shown in the cohort from 
Paris.34 In comparison, there are relatively 
few reports from outside Europe and the 
US.21 
 Cheung estimates the incidence of 
MIS-C as being 2 per 100,000 individuals 
aged 21 years and under.35 From Queens, 
New York, the publication by Capone et al. 
mentions 33 children in one hospital alone.38 
In a larger US cohort study involving 186 
children, no children under the age of 1 
showed positive IgG results.10 An MMWR 
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publication collected data from all US 
regions up to July 29, 2020, and identified 
570 cases with a median age of 8 years, 
predominantly male, from the Hispanic or 
Latino group.39 
 Data as of the end of May 2020, in 
France, had 156 cases of MIS-C. All cases 
can be grouped into four parts, namely, 
confirmed SARS-CoV-2 cases (79), 
probable (16), possible (13), and 
unrelated/inconclusive (48). Positive 
serology test results were found in 42 out of 
the156 cases. Positive PCR results were 
present in 28 cases. The median age was 
eight years.40 
 In Asia, reports have mainly come 
from Iran. The first reports were known 
since late May 2020.41 In Peru, the first 
reports were known since June 1, 2020, in a 
child of 3 years of age.42 
PATHOGENESIS 
 Similar to KD, the pathogenesis of 
MIS-C is not fully known. Patients had 
previously been infected with SARS-CoV-2; 
this was proved by mostly positive 
immunoglobulin tests.8,9,14,20,30,38,43,44 Even 
so, none of them had ever experienced 
severe symptoms before the episode. This 
indicates that the previous SARS-CoV-2 
infection was asymptomatic or with mild 
symptoms that the children and the parents 
did not realize. The results of PCR 
examinations for all MIS-C patients were 
mostly negative, even though there were 
publications that reported a positive rate of 
69% in the body. The time between the 
virus’s presence and the onset of symptoms 
and signs is about four weeks.14,30,38,45,46 
Feldstein found an interval of 22 days.10 In 
publications with many positive PCR 
results, all patients showed low viral loads.34 
A British cohort study (8 cases) of those 
who underwent an IgG isotype examination 
turned out to have detectable levels of IgG1 
and three but not IgG2 and 4. This was 
different from the results of examinations in 
adults.47 
 The process in MIS-C is relatively 
severe and is considered as a manifestation 
of a delayed immune response with 
uncontrolled inflammation. The result is 
damage to the host tissue.48 
 The infection has long been known 
to be one of the triggers for inflammatory 
and autoimmune diseases, mainly suspected 
through molecular mimicry pathways.12 The 
ECDC report mentions that microorganisms 
found in patients with MIS-C may occur 
later and are a trigger for MIS-C without 
direct relation to SARS-CoV-2 infection.16 
Until now, it is not clear which mechanism 
occurs. 
Online ISSN 2623-2723, Print ISSN: 2338-0373  Jurnal Widya Medika Vol. 6 No 2 Oktober 2020 
 
 
 SARS-CoV-2 infection is thought to 
trigger the emergence of antibodies against 
virus surface epitopes. Low levels of non-
neutralizing antibodies can increase the 
stimulation of the immune response 
triggered by the virus so that the risk of 
worsening disease becomes even greater.8,49 
Antibodies that block the ACE-receptor 
binding region are believed to be protective, 
but antibodies to nucleocapsids and other 
epitopes in proteins S is not.50 The virus 
coated with weak antibodies then undergoes 
internalization through the Fc receptor, 
followed by endosomal release from the 
virion. After that, the TLR and cytosolic-
RNA sensors will trigger an IFNᵧ response. 
This antibody-dependent enhancement 
(ADE) mechanism determines the 
immunological injury triggered by SARS-
CoV-2. This has been proven in COVID-
1951, but in MIS-C, it has not been fully 
revealed.52 
 Coronaviruses could block the 
response to interferon types I and III by 
delaying cytokine storms in patients whose 
immune responses cannot control viral 
replication and are characterized by high 
viral loads.53,54 This may also occur in cases 
with MIS-C. 
 In both KD and MIS-C, infection-
induced vasculitis was found.8 All 
inflammatory processes in MIS-C are more 
severe than those seen in KD.8,9,13,14,24 
 The phenomenon of cytokine storms 
in COVID-19 is characterized by an increase 
in proinflammatory cytokines and 
macrophages’ activation. In KD, an increase 
in proinflammatory cytokines is also seen as 
in other autoimmune diseases.21 
 The immunological profiles of 8 
patients in New York showed exposure to 
SARS-CoV-2 antibodies with normal 
isotype-switching and neutralization 
abilities. There were also increases in IL-8 
and IL-16, which indicate inflammatory 
activation, increased chemotaxis, and 
activation of lymphocytic and myeloid 
(CCL3, CCL4, and CDCP1), and 
dysregulation of the mucosal immune 
system (IL-17A, CCL20, and CCL28). In 
addition, extravasation to the affected tissue 
was also shown, and increased ICAM1 and 
FcᵧR1 in neutrophils and monocytes.55 The 
composition of the cytokines in KD and 
MIS-C was different.56,57 
 Genetic aspects are thought to play a 
role in MIS-C, as is seen in KD 
patients.8,58,59 From this genetic aspect, the 
TMEM173 gene’s role that regulates STING 
function in humans might be similar to that 
in bats and herpes viruses. STING is also 
overexpressed in arterial aneurysms. 
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Overactivation of STING will then cause 
hypercoagulability through the release of 
IFNβ and tissue factors by macrophage 
monocytes.60 The effect of genetic aspects is 
also seen in family clusters of KD. Some of 
the symptoms and signs of COVID-19 may 
also be familial.61 
The question is whether SARS-CoV-2 
directly triggers MIS-C or if it is just a 
primary, intermediate, or co-stimulatory 
agent, or whether SARS-CoV-2 provides an 
entry point for the true trigger.62 
 Nakra argues that MIS-C is stage II 
of the course of COVID-19 or a delayed 
immunological phenomenon associated with 
inflammation. Phases I and II in the course 
of COVID-19 are the acute and pulmonary 
phases.63 Direct infection by SARS-CoV-2 
does not play a role in MIS-C.63 Some of the 
differences between MIS-C and KD still 
require further exploration.64 
CLINICAL SYMPTOMS AND SIGNS 
 Symptoms and clinical signs of MIS-
C are mostly similar to KD or TSS or 
unusual gastrointestinal symptoms 
accompanied by very high inflammatory 
markers.8,9,11,14,20,38,63 The ACR mentions 
that the clinical symptoms are fever, 
mucocutaneous symptoms (rash, 
conjunctivitis, palm edema, dry and cracked 
lips, and strawberry tongue), myocardial 
disorders, heart conduction disorders, 
gastrointestinal symptoms, and enlarged 
glands.24 Other manifestations include 
neurological aspects of headache, cranial 
nerve palsy, altered mental status, or 
meningismus.24 The Presbyterian Children’s 
Hospital in New York mentions five things 
that can be found in MIS-C patients, 
namely, systemic inflammation (fever, 
myalgia, tachycardia, hypofusion or 
hyperfusion, and lymphadenopathy), 
cardiopulmonary symptoms (respiratory 
distress, chest pain), neurological symptoms 
(headache, change in status, mental, 
meningismus, focal deficits, and 
convulsions), mucocutaneous (rash, swollen 
lips, chapped lips, strawberry tongue, 
swelling of the extremities, conjunctivitis, 
and blisters or erosions), and gastrointestinal 
symptoms (nausea, vomiting, diarrhea, or 
abdominal pain). The hospital also divided 
clinical degrees into 3, namely, mild, 
moderate, and severe. The bases for this 
classification were vasoactive needs, support 
for breathing, and the presence of organ 
injury.65 The RCPCH guidelines stated that 
all cases presented with a 38.5°C fever or 
more, and a majority had hypoxia and 
hypotension. The clinical features include 
the following: abdominal pain, 
conjunctivitis, cough, diarrhea, headache, 
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confusion, enlarged glands, mucosal 
changes, swelling of the neck, rash, 
respiratory symptoms, sore throat, swelling 
of hands and feet, and vomiting.22 The 
systematic review by Abrams et al. 
described 87% of cases as having 
gastrointestinal signs and symptoms, 73% 
with dermatological/mucocutaneous, and 
71% with cardiovascular symptoms.20 Only 
47% of patients have respiratory symptoms 
and signs. Several recent case reports also 
mentioned common psychiatric and 
neurological manifestations (21%).20 
 A publication from France in 35 
children with MIS-C with acute heart failure 
has a predominance of gastrointestinal 
symptoms (80%).15 In another publication 
reporting about 156 children in France, 
about two-thirds showed Kawasaki-like 
features and had myocarditis.40 
 The report by Loke et al. regarding 
130 children with MIS-C in 5 countries 
(Italy, France, Switzerland, the USA, and 
the UK), and publications by Capone et al. 
from New York, USA, also found a 
predominance of gastrointestinal symptoms 
and signs.21,38 This is different from what is 
seen in KD.15,21 
 Gastrointestinal disorders can 
include vomiting, diarrhea, or abdominal 
pain.13 Pancreatitis has also been reported.66 
Abdominal pain in MIS-C cannot be ignored 
because in the publication by Tullie et al., 
most of the children were suspected of 
having appendicitis when they arrived at the 
hospital. The radiological examination 
makes clinicians more aware of this.67 
Several cases have undergone surgery 
because of this initial suspicion, and 
clinicians found mesenteric lymphadenitis 
and appendicitis.63 
 Rowley suggested that the focus of 
exploration should always be more intensive 
on gastrointestinal and cardiovascular 
aspects.64 A New York cohort study had 44 
children with MIS-C who showed 
predominant gastrointestinal system 
symptoms, apart from fever (100%) and rash 
(70%).68 A similar condition with 
gastrointestinal predominance was also seen 
in a cohort study of 78 cases admitted to 
various PICUs in the UK. The number of 
people suffering from shock in this group 
was 87%.31 
 In the Whittaker report, which 
included 58 children who presented with 
fever, abdominal pain was present in about 
half of the cases. Diarrhea and rashes were 
also in the same proportion.8 There were 
three groups observed in the publication: 
those with fever and increased markers of 
inflammation but without a complete picture 
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of KD, TSS, or organ failure, a group with 
shock and left heart disorders, and groups 
that meet the KD criteria.8 
 Cardiovascular disorders can be in 
the form of left-heart dysfunction, coronary 
artery dilatation, and conduction 
disorders.15,24 What distinguishes KD is the 
fact that cardiac dysfunction was not too 
dominant.15,21,24,38,69 
 A British cohort study that examined 
several modalities and at least two devices 
for the heart alone (20 patients) showed 
different things. From the beginning, 
abnormal Doppler results were detected. The 
ejection fraction is less than 55% in half of 
the cases and continues to worsen during 
treatment until it finally gets better when the 
patient is discharged. The left coronary 
artery’s diameter was greater when the 
patient went home than when he was 
admitted to the hospital. More widening was 
seen in the left coronary artery (9 out of 12 
cases).70 
 Neurological symptoms and shock 
that are also found in MIS-C are not the 
principal phenomena in KD.24 Neurological 
symptoms can be status epilepticus.71,72 In 
the case described by Schupper, the patient 
also exhibited multifocal echogenicity and 
infarction of several parts of the cerebral 
arteries.72 Another report stated that patients 
were restless, agitated, and confused.73 In 
other cases, diffuse brain hemosiderosis and 
clonus were found.74 There were also 
headaches, irritability, and 
encephalopathy.63 
 US data shows that 490 out of 570 
cases involving at least four organs. There 
were 99/570 cases involving at least six 
organ systems (with a proportion of 100% 
cardiovascular system and 97.5% 
gastrointestinal system). About 98% of this 
group had positive SARS-CoV-2 serology 
results. About two-thirds of cases do not 
have co-morbidities. The organs involved 
are gastrointestinal (90%), cardiovascular 
(86.5%), and mucocutaneous (70.9%). The 
most common symptoms and clinical signs 
are abdominal pain, vomiting, rash, diarrhea, 
hypotension, and red-eye.39 The group with 
obvious respiratory symptoms may still be 
partly due to COVID-19. The patient has a 
cough, shortness of breath, pneumonia, and 
respiratory failure syndrome. Most of this 
group still showed positive PCR results with 
negative serology results. Mortality in this 
group was higher.39 The group dominated by 
rash and mucocutaneous symptoms was 
lower in age and had more coronary artery 
dilatation. This group was more suitable 
with a complete KD.39 
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A US cohort with 191 cases in New York 
was mostly male and Hispanic.30 All 
patients presented with fever, 97% with 
tachycardia, 80% with gastrointestinal signs, 
and 60% with rashes.30 A separate 
publication of 15 of the first cases at a 
referral hospital in New York showed 
substantially interesting results.75 
 The New York cohort (33 cases) had 
fever and mutation as the chief complaints,32 
while the Paris cohort of 21 children and 
adolescents had 12 presenting with KDSS, 
16 with myocarditis, and all of them had 
gastrointestinal complaints at the early 
phase.14 
 A New York cohort of 17 patients 
found all cases had fever and 14 children 
had gastrointestinal complaints. 
Mucocutaneous symptoms were common, 
with 12 patients exhibiting rashes, 11 with 
conjunctivitis, and 9 with lip swelling. Eight 
cases met the KD criteria and five as 
incomplete KD.35 Feldstein et al. reported a 
US cohort with 186 cases that experienced 
involvement of gastrointestinal, 
cardiovascular, hematologic, 
mucocutaneous, and respiratory organs in 
92%, 80%, 76%, 74%, and 70% of the total 




 As with KD, there is no definitive 
test for MIS-C.16,20,22-24 Some guidelines 
state that all cases show fibrinogen 
abnormalities, high CRP/D-Dimer/Ferritin, 
hypoalbumin, lymphopenia, usually low 
neutrophils, and no evidence of infection 
with specific microorganisms. Some of them 
also have laboratory features such as acute 
kidney injury, anemia, coagulopathy, 
elevated IL-10 and IL-6, neutrophilia, 
proteinuria, elevated CK and LDH, 
thrombocytopenia, and transaminitis. 
Various publications mentioned these 
results.16,20,22-24,31,46,63,64,68 ACR recommends 
a 2-stage laboratory examination to show 
priority scale and time considerations.24 
Reports from Italy, France, England, and the 
US also mentioned that children with MIS-C 
showed significant lymphopenia and 
thrombocytopenia, coagulopathy, increased 
cardiac enzymes such as troponin, 
hyponatremia, hypoalbuminemia, and 
increased lactate dehydrogenase and ferritin. 
This phenomenon is only slightly found in 
people with KD.8,9,14,15,31,38,46,68,76 Abrams 
said that at least 75% of patients had high 
CRP levels, IL-6, and fibrinogen.20  The 
descriptions of 5 cytokines (IFN-ᵧ, IL-10, 
IL-6, IL-8, and TNF-α) have been analyzed 
to differentiate MIS-C and KD, and the 
Multisystem Inflammatory Syndrome  Husada D 
146 
 
significant differences were only in TNF-α 
and IL-10.76 
 Laboratory data of US patients show 
different results between groups. The group 
with six or more organ involvement 
predominantly of gastrointestinal and 
cardiovascular symptoms and signs showed 
higher D-dimer, troponin, BNP, proBNP, 
and ferritin. This group has lower 
lymphocytes. The group with dominant 
mucocutaneous symptoms had the lowest D-
dimer levels, troponin, BNP, proBNP, CRP, 
and ferritin, but the highest lymphocyte 
levels.39 A New York cohort of 191 cases 
had increased CRP, D-dimer, and troponin 
in 100%, 91%, and 71% of cases.30  
 A US cohort with 186 cases had 
increased four or more inflammation 
markers in 92% of patients.10 A New York 
cohort of 17 children had increased 
inflammation markers in all cases, 
predominantly lymphopenia, bandemia, 
elevated troponin T, and proBNP. IL-2R, 
IL-18, and CXCL 9 were elevated in all 
cases. IFNᵧ and IL-8 increased in only a few 
cases.35 
 Ferritin and D-dimer increased in 
half of the patients. CRP, IL-6, and 
fibrinogen are even increased in 75% of 
patients. The increase in heart damage 
markers such as troponin and brain 
natriuretic peptide (BNP) has reached 100% 
in several publications.20,46 
 Verdoni reported that MIS-C patients 
had lower levels of leukocytes and platelets 
than Kawasaki patients, but with higher 
CRP and ferritin.9 Whittaker et al. reported 
that MIS-C patients had higher levels of 
neutrophils, CRP, ferritin, troponin, and D- 
dimer but with lower lymphocytes and 
platelets levels.8 The same results were 
demonstrated in the study of Belhajer et al.15 
A New York cohort of 33 children showed 
increased CRP, procalcitonin, D-Dimer, and 
proBNP.32 
 Examination of heart markers is 
highly recommended considering the 
proportion of heart problems in cases with 
MIS-C.15,17,24,38,46,76,77 A UK cohort of 15 
cases with cardiovascular symptoms and 
signs showed increased CRP, ferritin, 
troponin, creatine kinase, and proBNP.78 
There were 10 cases with valve 
regurgitation, and 12 showed decreased left 
ventricular ejection. A total of 14 out of the 
15 cases showed coronary artery 
abnormalities, but ECG abnormalities were 
only found on 6 out of 15.78 Radiological 
features may include patchy infiltrates and 
pleural effusions (Plain chest radiograph, CT 
scan for the thorax). Abdominal ultrasound 
may show colitis, ileitis, lymphadenopathy, 
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ascites, and hepatosplenomegaly. The results 
of echocardiography and ECG include 
myocarditis, valvulitis, pericardial effusion, 
and coronary artery dilatation.16,22-24 Some 
earlier patients did not show a specific ECG 
pattern. Later, these children got worse, and 
some had to be admitted into the PICU.15,38 
Plain chest radiographs and CT scans are 
required not only for the MIS-C but also to 
detect COVID-19.24 Of the 16 children in 
the US, the most common chest radiological 
images include cardiomegaly, pulmonary 
edema or congestive heart failure, 
atelectasis, pleural effusion, and 
pneumonia.79 The results of 
echocardiography examinations in the US, 
in addition to coronary artery aneurysms, 
also show much left or right heart valve 
dysfunction, pericardial effusion, and mitral 
regurgitation.77  
 A UK cohort of 35 children has 
airway inflammation and pulmonary edema 
(which can be seen rapidly on chest 
radiology), and coronary artery aneurysms. 
The most common results of chest 
radiographs are peribronchial cuffing and 
perihilar interstitial thickening. For a chest 
CT scan, the most common result was basal 
consolidation and pleural effusion. A cardiac 
CT scan also shows decreased myocardial 
function, myocarditis, pancarditis, and 
pericardial effusion. The abdominal 
radiology results showed that there was an 
excessive inflammatory change in the right 
quadrant of the iliac fossa.80 
 In France, cardiac MRI images of the 
cohort in Paris showed a mixed picture, 
whereas echocardiography revealed low or 
normal low left heart function.81 In the 33 
cases reported by Capone et al. in New 
York, USA, hemodynamic instability and 
cardiac dysfunction were the main features. 
All cases improved quickly after receiving 
anti-inflammatory therapy.38 Meanwhile, in 
the 33 cases reported by Kaushik et al., 
about 63% showed a decreased left 
ventricular ejection fraction.32 
 Of 44 children in New York, some 
abnormalities were mesenteric adenitis, 
acalculous cholecystitis or biliary sludge, 
and ascites.68 For abdominal radiology, the 
results are ascites, hepatomegaly, thickening 
of the intestinal wall and bladder, echogenic 
kidneys, mesenteric lymphadenopathy, and 
splenomegaly.79 
 Laboratory examinations at Mount 
Sinai, New York, found that 87% out of 15 
children had gastrointestinal manifestations, 
including vomiting, abdominal pain, and 
diarrhea. Only less than half showed a 
picture of KD. Tachycardia and hypotension 
were present in 87% of cases.75 Cardiac 
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involvement was found in 87% of cases that 
involved elevated serum troponin or 
proBNP. Lymphopenia is present in 87% of 
patients, while thrombocytopenia and 
hypoalbuminemia are present in only about 
half of cases. Fibrinogen increases in 93% of 
cases.75  
DIAGNOSIS 
 There is no definitive test to 
diagnose MIS-C. Inclusion criteria or case 
definitions may vary depending on the 
guidelines followed. Laboratory 
examination results can also vary.20,63 The 
diagnosis of MIS-C is more of a syndromic 
diagnosis. 
 Inclusion criteria for case definitions 
according to the RCPCH 2020 guidelines 
are children with fever, inflammation 
(neutrophilia, increased CRP, and 
lymphopenia), and evidence of dysfunction 
of one or more organs (shock, cardiac, 
respiratory, renal, gastrointestinal, or 
nervous system disorders) plus multiple 
additional manifestations (clinical, 
laboratory, imaging, electrocardiogram). 
These guidelines also mention “including a 
complete and partial picture of Kawasaki 
Disease”. MIS-C cases should be screened 
to exclude cases of bacterial infections, 
including Staphylococcus and streptococcus 
that also cause TSS, as well as cases of viral 
infections associated with myocarditis, such 
as those caused by enteroviruses. The 
RCPCH does not mandate a negative PCR 
examination.22 
 On the other hand, the CDC sets the 
following case boundaries: individuals under 
21 years of age with fever, laboratory 
evidence showing inflammation, and 
evidence of serious clinical conditions 
requiring hospitalization, with more than 
two organs involved (cardiac, renal, 
respiratory, hematological, gastrointestinal, 
dermatological, and neurological), as well as 
the absence of other possible diagnoses, and 
the presence of evidence of SARS-CoV-2 
infection with RT-PCR, serology, antigen 
testing, or exposure within four weeks 
before the appearance of clinical signs or 
symptoms.23 
 The WHO statement on 15 May 
2020 stated the following criteria: children 
aged less than 19 years with a history of 
fever for more than three days, accompanied 
by at least 2 of the following signs:25 
(1) Rash or bilateral non-purulent 
conjunctivitis or signs of 
mucocutaneous inflammation (in the 
mouth, hands, or legs) 
(2) Hypotension or shock 
(3) Myocardial dysfunction, pericarditis, 
valvulitis, or coronary abnormalities 
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(including echocardiography results 
or elevated troponin/NT-proBNP) 
(4) Evidence of coagulopathy (PT, PTT, 
elevated D-dimers) 
(5) Acute gastrointestinal problems 
(diarrhea, vomiting, or abdominal 
pain)  
(6) An increase in inflammatory markers 
such as sedimentation rate, CRP, or 
procalcitonin 
(7) No clear evidence of microbes 
causing inflammation (including 
bacterial and staphylococcal sepsis 
or streptococcal shock syndrome) 
(8) Evidence of SARS-CoV-2 infection 
(RT-PCR, antigen or serology 
testing) or exposure to a COVID-19 
patient 
  Both the CDC and the WHO 
require evidence of SARS-CoV-2 infection 
or previous exposure to patients. This, of 
course, is quite problematic considering the 
number of asymptomatic cases and the 
limitations of diagnostic methods.28 
MANAGEMENT 
 During the pandemic, the treatment 
of cases with heart problems has become 
somewhat neglected because heart patients 
are afraid to come to the hospital and 
because doctors may be so concentrated on 
COVID-19 cases that they are somewhat 
“forgetting” other cases.27,82 
 The goals of MIS-C management are 
to reduce systemic inflammation and restore 
organ function, and reduce the risk of death 
and long-term sequelae (such as cardiac 
disorders).63 Some experts suggest that 
treatment is given according to clinical 
manifestations. The largest group, which 
resembled KD, was given treatment similar 
to that in KD management, while the TSS-
like group was given the TSS-like 
procedure, and in some places, empiric 
antibiotics (preceded by sampling for blood 
cultures) are mentioned. In all cases, it must 
be considered that there is a presence of 
SARS-CoV-2 infection, so personal 
protective equipment is compulsory. 
 As the situation deteriorates rapidly, 
close surveillance of the cardiorespiratory 
system includes continuous saturation and 
ECG with blood pressure monitoring. EKG 
examination is initiated from the time the 
patient arrives.22,23,63 
 Administration of Remdesivir can be 
done, but there is no strong evidence to 
support it. Antibiotics can be understood 
because clinical manifestations also 
resemble a severe bacterial infection.63 In 
conditions similar to KD, intravenous 
immunoglobulin at a dose of 2 g/kg of 
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weight can be given. Immunoglobulins are 
given slowly under adequate supervision of 
the conditions. Aspirin at a dose of 30 
mg/kg BW is also given and maintained 
until the patient is discharged from the 
hospital or until the inflammatory picture 
has improved.16,19,22-24,46 Administration of 
immunoglobulins in MIS-C often requires 
repetition.20,21,34  A Paris cohort, for 
example, found that 10 out of 16 children 
require repeat therapy.34 
 Other therapies given are steroids 
(52% of cases) and immunomodulators.20,63 
The report by Belhajer et al. mentions that 
25 out of 35 children received 
immunoglobulins, and half of them also 
received steroids.15 A Harvard cohort study 
in Boston, USA, reported that 71% are 
receiving immunoglobulins, 61% are 
receiving steroids, and 18% are receiving 
anakinra.46 In New York, out of 44 children, 
steroids were given in 95%, 
immunoglobulins in 81%, and 90% received 
anticoagulants.68 The British cohort study 
found the use of immunoglobulins and 
steroids in more than 70% of patients.31 
 Of the US cohort, 80.5% received 
immunoglobulins, and 62.8% received 
steroids. About 40% of cases received 
anticoagulants and vasoactive drugs.39 Of 
the 33 children in New York, half received 
immunoglobulins, half also received 
steroids, and around half also received 
vasopressors. Five people received 
mechanical ventilation.32 Of the 21 children 
in Paris, all received immunoglobulins, and 
10/21 also received steroids.14 All patients 
improved. In a cohort of 17 children in New 
York, 13 received immunoglobulins, and 14 
received steroids.35 
 Some publications also mention IL-1 
receptor antagonist (anakinra), TNF-α 
antagonist (infliximab), and IL-6 antagonist 
(tocilizumab) as adjuncts to 
therapy.20,31,36,46,63,83 Heparin can be given 
for severely impaired ventricular function. 
Low doses of heparin can be considered in a 
non-severe situation because of the 
thromboembolism risks.83 
 A New York cohort of 191 cases 
showed that 62% of patients received 
vasopressors, and 80% had to be admitted to 
the PICU. Two patients died.30 Another US 
cohort of 186 cases from 26 states showed 
that 80% of patients had to be admitted to 
the PICU, 48% received vasopressors, and 
only 20% required mechanical ventilation. 
Immunoglobulins were administered in 
77%, steroids in 44%, and IL-6 or IL-1RA 
inhibitors in 20% of cases.10 
 In MIS-C shock, fluid resuscitation 
to treat circulatory collapse may be given. 
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Certain drugs also play a role when fluids do 
not work.8,9,13,14 In conditions similar to 
TSS, intravenous immunoglobulin may also 
be given. 
 Multi-organ involvement should 
always be sought. If there is cardiological 
involvement (elevated troponin, ECG 
changes, echocardiographic abnormalities), 
prompt cardiological action and surveillance 
were needed.22,23,63 
 As many as 26% of patients had to 
be on a ventilator, and 6% even needed 
extracorporeal membrane oxygenation 
(ECMO).20 Of the UK cohort, only 3 out of 
78 children, needed ECMO.31 Data on 156 
cases in France found that 67% required 
treatment in the PICU. Of these, two-thirds 
received vasopressors, and half received 
mechanical ventilation.40 In a cohort of 8 
patients in the UK, six required treatment at 
the PICU.47 
COMPLICATIONS 
 The main complication for both KD 
and MIS-C is the dilatation of the coronary 
arteries. The incidence of this complication 
ranges from 20%–25% in both diseases.13 In 
a UK cohort study, there was an even 36% 
of cases with dilated coronary arteries.31 Not 
many patients with MIS-C had large 
aneurysms. Most cases of MIS-C were 
resolved in a short period and rarely got 
worse.8,9,11,13 Long-term side effects are not 
known.11 
 US data show the most 
complications are cardiac dysfunction 
(40.6%), shock (35.4%), myocarditis, 
coronary artery dilation, and acute kidney 
injury.39 All children in Belhajer’s study 
even had heart problems (35/35) but 
eventually improved.15 Of the USA cohort 
studies above, about two-thirds of patients 
were admitted to the PICU. The incidence of 
complications was higher in the younger 
group and showed mucocutaneous signs and 
symptoms.39  
PROGNOSIS 
 The prognosis for MIS-C patients is 
relatively good, and recovery occurs 
faster.11,15,17,24,38,84,85 Of those who have 
dilated coronary arteries, most of them also 
heal as usual in a short time. Until now, it 
has not been confirmed whether MIS-C is a 
severe variant of KD triggered by SARS-
CoV-2 infection or MIS-C is a separate 
disease that can be mild to severe and 
resembles KD, or TSS.11,17,20 Clinicians 
suspect that the two diseases are distinct 
entities with some phenotypic aspects in 
common.17,20,43,63,86 
 The case fatality rate from various 
countries in children with MIS-C is 
relatively low.9,10,14,20,30,35,87 Only two of the 
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78 children treated at the PICU in the UK 
have died. One of them had an arrhythmia 
that was due to cerebral infarction.13,31,43 
Two other reports came from New York.8,21 
Total deaths across the US 10 cases.39 The 
group with higher mortality is which shows 
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